血漿タンパク質治療薬市場：製品、用途別-2025-2030年の世界予測

血漿タンパク質治療薬市場は、2023年に325億5,000万米ドルと評価され、2024年には361億9,000万米ドルに達すると予測され、CAGR 11.37％で成長し、2030年には691億8,000万米ドルに達すると予測されています。

血漿タンパク質治療薬には、血友病、免疫不全、希少疾患などの疾患に対するヒト血漿タンパク質由来の治療が含まれます。免疫グロブリン、アルブミン、凝固因子など、重要な患者のニーズに合わせて設計された治療薬が含まれます。その必要性は、これらのタンパク質が提供するユニークな治療効果にあり、多くの場合、代替手段を持たない患者にとって不可欠なものです。凝固障害や免疫不全の治療・管理から救急医療におけるクリティカルケアまで、その用途は多岐にわたる。最終用途は主に病院、専門クリニック、研究機関であり、そこでは効果的な治療法が切実に必要とされています。市場は、希少疾患の増加、血漿分画の技術的進歩、ヘルスケア支出の増加などの要因によって牽引されています。最新のビジネスチャンスは、免疫グロブリンの需要急増と遺伝子組換え療法の技術革新に加え、ヘルスケア・インフラの改善による新興地域での市場拡大によってもたらされます。こうした機会を活用するため、企業は戦略的パートナーシップや地域拡大に注力すべきです。しかし、現在のところ、治療費の高騰、厳しい規制の枠組み、血漿提供をめぐる倫理的問題などの制約が市場成長の課題となっています。さらに、製品製造の複雑さや限られた血漿供給が大きなハードルとなっています。技術革新のための最良の分野としては、新しい血漿由来の治療法の開発、血漿採取効率の向上、遺伝子組み換え代替品を改良するための遺伝子工学の探求などが挙げられます。市場は激しい競合が主な特徴で、戦略的合併、買収、提携が成長を促進する上で一般的です。企業は、新規治療薬や潜在的な合成代替品の研究への投資を優先し、供給を拡大すべきです。全体として、市場は技術革新とアクセスの拡大により成長する態勢にあるが、コスト、規制、サプライチェーンの複雑さという課題を克服しなければならないです。

市場力学：急速に進化する血漿タンパク質治療薬市場の主要市場インサイトを公開

血漿タンパク質治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 自己免疫疾患および神経疾患の有病率の増加
  • 患者の生涯を通じた定期的な輸液または注射の必要性
  • 血漿蛋白質治療への患者のアクセスと手頃な価格の急増
• 市場抑制要因
  • 血漿タンパク質治療薬の副作用
• 市場機会
  • 血漿蛋白質に関する研究開発活動の活発化
  • 効率的な血漿タンパク質抽出/製造プロセスの開発
• 市場の課題
  • 血漿タンパク質の取り扱いに関する厳しい規制

ポーターの5つの力：血漿タンパク質治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血漿タンパク質治療薬市場における外部からの影響の把握

外部マクロ環境要因は、血漿タンパク質治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血漿タンパク質治療薬市場における競合情勢の把握

血漿タンパク質治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血漿タンパク質治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血漿タンパク質治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 自己免疫疾患および神経疾患の罹患率の増加
    • 患者の生涯を通じて定期的な点滴や注射の必要性
    • 患者にとって血漿タンパク質療法へのアクセスと手頃な価格の急増
  • 抑制要因
    • 血漿タンパク質治療薬の悪影響
  • 機会
    • 血漿タンパク質に関する研究開発活動の増加
    • 効率的なタンパク質血漿抽出・製造プロセスの開発
  • 課題
    • 血漿タンパク質の取り扱いに関する厳格な規制
• 市場セグメンテーション分析
  • 製品：HAEに伴う腫れの発作を抑制および予防するためのC1エステラーゼ阻害剤の使用増加
  • 応用：がんや自己免疫疾患の蔓延による二次免疫不全における血漿タンパク質治療薬の応用が拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 血漿タンパク質治療薬市場：製品別

• アルブミン
• C1エステラーゼ阻害剤
• 凝固因子
• 高度免疫グロブリン
• 免疫グロブリン

第7章 血漿タンパク質治療薬市場：用途別

• 遺伝性血管性浮腫
• 特発性血小板減少性紫斑病
• 原発性免疫不全症
• 二次免疫不全症

第8章 南北アメリカの血漿タンパク質治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の血漿タンパク質治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの血漿タンパク質治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • GCバイオファーマ、インドネシアの血漿分画工場の起工式
  • プラズマジェン・バイオサイエンス、バンガロールのコラールに最先端の血漿製品製造施設を新設
  • 武田薬品、日本に7億7,000万米ドルの血漿分画療法工場を建設へ

企業一覧

• Bio Products Laboratory Ltd.
• CSL Limited
• Takeda Pharmaceutical Company Limited
• DiaPharma
• GC Biopharma corp
• AmerisourceBergen Corporation
• Laboratory Corporation of America Holdings
• Bruker Corporation
• Octapharma AG
• KalVista Pharmaceuticals
• Emergent BioSolutions
• FFF Enterprises, Inc.
• Plasma Technologies, LLC
• LFB SA
• Kamada Ltd.
• PlasmaGen BioSciences Pvt. Ltd.
• Reliance Industries Limited
• Thermo Fisher Scientific, Inc.
• Grifols, S.A.
• China Biologic Products Holdings, Inc.
• Hemarus Therapeutics Limited
• Access Biologicals LLC
• ADMA Biologics, Inc.
• Baxter International Inc.
• Kedrion S.p.A.

LIST OF FIGURES

• FIGURE 1. PLASMA PROTEIN THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PLASMA PROTEIN THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 105. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Plasma Protein Therapeutics Market was valued at USD 32.55 billion in 2023, expected to reach USD 36.19 billion in 2024, and is projected to grow at a CAGR of 11.37%, to USD 69.18 billion by 2030.

Plasma Protein Therapeutics involves treatments derived from human plasma proteins for diseases such as hemophilia, immune deficiencies, and rare disorders. The scope encompasses therapies like immunoglobulins, albumin, and clotting factors designed for critical patient needs. The necessity lies in the unique therapeutic benefits these proteins offer, often essential for patients who lack alternatives. Applications extend from treatment and management of clotting disorders and immune system deficiencies to critical care in emergency medicine. End-use is primarily in hospitals, specialized clinics, and research institutions, where there is a dire need for effective therapies. The market is driven by factors like increasing prevalence of rare diseases, technological advancements in plasma fractionation, and rising healthcare expenditure. Latest opportunities arise from the surge in demand for immunoglobulins and innovations in recombinant therapies, coupled with market expansion in emerging regions due to improving healthcare infrastructure. To capitalize on these opportunities, businesses should focus on strategic partnerships, and regional expansions. However, market growth is currently challenged by constraints such as the high cost of therapies, stringent regulatory frameworks, and the ethical issues surrounding plasma donation. Additionally, complexities in product manufacturing and limited plasma supply pose significant hurdles. The best areas for innovation include developing new plasma-derived therapies, enhancing plasma collection efficiency, and exploring genetic engineering to improve recombinant alternatives. The market is primarily characterized by intense competition, where strategic mergers, acquisitions, and collaborations are common in fostering growth. Businesses should prioritize investment in research for novel therapies and potential synthetic alternatives to boost supply. Overall, the market is poised for growth, driven by innovations and expanding access, but must navigate the challenges of cost, regulation, and supply chain complexities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Protein Therapeutics Market

The Plasma Protein Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased Prevalence of Autoimmune and Neurological Diseases
  • Need for Regular Infusions or Injections Throughout the Life of the Patient
  • Surging Access and Affordability of Plasma Protein Therapies for Patients
• Market Restraints
  • Adverse Effects of Plasma Protein Therapeutics
• Market Opportunities
  • Increasing Research and Development Activity Related to the Plasma Protein
  • Development of Efficient Protein Plasma Extraction/Manufacturing Process
• Market Challenges
  • Strict Regulations Pertaining to Handling of Plasma Protein

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Protein Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Protein Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Protein Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Protein Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Protein Therapeutics Market

A detailed market share analysis in the Plasma Protein Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Protein Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Protein Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Bio Products Laboratory Ltd., CSL Limited, Takeda Pharmaceutical Company Limited, DiaPharma, GC Biopharma corp, AmerisourceBergen Corporation, Laboratory Corporation of America Holdings, Bruker Corporation, Octapharma AG, KalVista Pharmaceuticals, Emergent BioSolutions, FFF Enterprises, Inc., Plasma Technologies, LLC, LFB SA, Kamada Ltd., PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Thermo Fisher Scientific, Inc., Grifols, S.A., China Biologic Products Holdings, Inc., Hemarus Therapeutics Limited, Access Biologicals LLC, ADMA Biologics, Inc., Baxter International Inc., and Kedrion S.p.A..

Market Segmentation & Coverage

This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.
• Based on Application, market is studied across Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Secondary Immunodeficiency.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Prevalence of Autoimmune and Neurological Diseases
    • 5.1.1.2. Need for Regular Infusions or Injections Throughout the Life of the Patient
    • 5.1.1.3. Surging Access and Affordability of Plasma Protein Therapies for Patients
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse Effects of Plasma Protein Therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Research and Development Activity Related to the Plasma Protein
    • 5.1.3.2. Development of Efficient Protein Plasma Extraction/Manufacturing Process
  • 5.1.4. Challenges
    • 5.1.4.1. Strict Regulations Pertaining to Handling of Plasma Protein
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
  • 5.2.2. Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Plasma Protein Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Albumins
• 6.3. C1-esterase Inhibitors
• 6.4. Coagulation Factors
• 6.5. Hyperimmune Globulins
• 6.6. Immunoglobulins

7. Plasma Protein Therapeutics Market, by Application

• 7.1. Introduction
• 7.2. Hereditary Angioedema
• 7.3. Idiopathic Thrombocytopenic Purpura
• 7.4. Primary Immunodeficiency Disorder
• 7.5. Secondary Immunodeficiency

8. Americas Plasma Protein Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Plasma Protein Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Plasma Protein Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
  • 11.3.2. PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
  • 11.3.3. Takeda to build USD 770 million plasma-derived therapy plant in Japan

Companies Mentioned

• 1. Bio Products Laboratory Ltd.
• 2. CSL Limited
• 3. Takeda Pharmaceutical Company Limited
• 4. DiaPharma
• 5. GC Biopharma corp
• 6. AmerisourceBergen Corporation
• 7. Laboratory Corporation of America Holdings
• 8. Bruker Corporation
• 9. Octapharma AG
• 10. KalVista Pharmaceuticals
• 11. Emergent BioSolutions
• 12. FFF Enterprises, Inc.
• 13. Plasma Technologies, LLC
• 14. LFB SA
• 15. Kamada Ltd.
• 16. PlasmaGen BioSciences Pvt. Ltd.
• 17. Reliance Industries Limited
• 18. Thermo Fisher Scientific, Inc.
• 19. Grifols, S.A.
• 20. China Biologic Products Holdings, Inc.
• 21. Hemarus Therapeutics Limited
• 22. Access Biologicals LLC
• 23. ADMA Biologics, Inc.
• 24. Baxter International Inc.
• 25. Kedrion S.p.A.